Parallax Volatility Advisers, L.P. Halozyme Therapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $1.25 Million - $1.62 Million	-33,600 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $604,233 - $776,034	-18,900 Reduced 36.0%	33,600 $1.34 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $2.04 Million - $2.69 Million	52,500 New	52,500 $2.38 Million
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $1.86 Million - $2.18 Million	-126,200 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $1.76 Million - $2.22 Million	126,200 New	126,200 $2.03 Million
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $667,200 - $736,400	-40,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $12.1 Million - $14.5 Million	-715,000 Reduced 94.7%	40,000 $675,000
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $5.64 Million - $7.01 Million	330,500 Added 77.86%	755,000 $14.8 Million
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $2.72 Million - $3.38 Million	-162,500 Reduced 27.68%	424,500 $8.6 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $6.9 Million - $10.2 Million	587,000	587,000 $10.2 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.